Paradigm Biocapital Advisors LP
Q1 2024 13F-HR Holdings
Net value change ($000)
+704,824
(33.0%)
New positions
10
Sold out positions
5
Turnover %
24.8%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| SRPT | 139,603 | NEW |
| RVMD | 93,950 | NEW |
| PCVX | 84,704 | NEW |
| TARS | 83,329 | 401.5% |
| ARVN | 69,613 | 181.6% |
| CRNX | 63,976 | 77.7% |
| ACLX | 62,495 | 30.8% |
| ARGX | 56,620 | 35.2% |
| KURA | 48,719 | 268.3% |
| EWTX | 44,622 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| Mirati Therapeutics, Inc. | -90,658 | -100.0% |
| Ambrx Biopharma, Inc. | -61,982 | -100.0% |
| AUTL | -40,220 | -49.5% |
| TGTX | -37,088 | -100.0% |
| ZLAB | -29,838 | -100.0% |
| OLMA | -21,419 | -19.3% |
| VRDN | -16,324 | -15.6% |
| CRBU | -5,587 | -33.3% |
| CRGX | -4,415 | -57.2% |
| JBIO | -3,241 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|